Seasonal Influenza A LAAb

About RQ Biotechnology

RQ Bio is a private, preclinical-stage biotechnology company developing a novel class of long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza. The company aims to address the significant unmet need in immunocompromised populations—such as newborns, the elderly, and patients with chronic conditions—who are at high risk of severe disease and often exhibit suboptimal responses to seasonal flu vaccines. By engineering antibodies for immediate and durable protection, RQ Bio seeks to mitigate the annual global threat posed by influenza's seasonal evolution, which undermines vaccine effectiveness. The company is headquartered in London and appears to be in a venture-backed, pre-revenue stage of development.

Therapeutic Areas